Cargando…

Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial

BACKGROUND: Among patients with atrial fibrillation and stable coronary artery disease, those with histories of atherothrombotic disease are at high‐risk for future ischemic events. This study investigated the efficacy and safety of rivaroxaban monotherapy in patients with atrial fibrillation, coron...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuzawa, Yasushi, Kimura, Kazuo, Yasuda, Satoshi, Kaikita, Koichi, Akao, Masaharu, Ako, Junya, Matoba, Tetsuya, Nakamura, Masato, Miyauchi, Katsumi, Hagiwara, Nobuhisa, Hirayama, Atsushi, Matsui, Kunihiko, Ogawa, Hisao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751847/ https://www.ncbi.nlm.nih.gov/pubmed/34658247 http://dx.doi.org/10.1161/JAHA.121.020907

Ejemplares similares

The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial
por: Matsui, Kunihiko, et al.
Publicado: (2022)

Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings
por: Arashi, Hiroyuki, et al.
Publicado: (2022)

Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis
por: Ishii, Mitsuru, et al.
Publicado: (2022)

Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories
por: Ishii, Masanobu, et al.
Publicado: (2022)

Risk prediction score for clinical outcome in atrial fibrillation and stable coronary artery disease
por: Ishii, Masanobu, et al.
Publicado: (2023)

AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies
por: Stein, AM, et al.
Publicado: (2017)

Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs
por: Patti, Giuseppe, et al.
Publicado: (2018)

Novel Antiplatelet Therapies for Atherothrombotic Diseases
por: Majithia, Arjun, et al.
Publicado: (2019)

Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases
por: Petrucci, Giovanna, et al.
Publicado: (2022)

Antiplatelet combinations for prevention of atherothrombotic events
por: Bollati, Mario, et al.
Publicado: (2011)

Hematopoiesis of Indeterminate Potential and Atherothrombotic Risk
por: Murphy, Andrew J., et al.
Publicado: (2022)

Unexplored Roles of Erythrocytes in Atherothrombotic Stroke
por: Papadopoulos, Charalampos, et al.
Publicado: (2023)

PCSK9 as an Atherothrombotic Risk Factor
por: Sotler, Tadeja, et al.
Publicado: (2023)

Medicinal Herbals with Antiplatelet Properties Benefit in Coronary Atherothrombotic Diseases
por: Mohd Nor, Nurul Huda, et al.
Publicado: (2016)

Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
por: Jourdi, Georges, et al.
Publicado: (2022)

Environmental noise exposure is associated with atherothrombotic risk
por: Koczorowski, Magali, et al.
Publicado: (2022)

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease
por: Dobesh, Paul P., et al.
Publicado: (2017)

Going “Green” in the Prevention and Management of Atherothrombotic Diseases: The Role of Dietary Polyphenols
por: Reis, Ana, et al.
Publicado: (2021)

The Role of Biomarkers in Atherothrombotic Stroke—A Systematic Review
por: Andone, Sebastian, et al.
Publicado: (2021)

Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk
por: Mauriello, Alfredo, et al.
Publicado: (2023)

Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options
por: Fintel, Dan J
Publicado: (2012)

Ways of Coping and Biomarkers of an Increased Atherothrombotic Cardiovascular Disease Risk in Elderly Individuals
por: von Känel, Roland, et al.
Publicado: (2012)

Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome
por: Pérez-Sánchez, Carlos, et al.
Publicado: (2018)

Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
por: Jourdi, Georges, et al.
Publicado: (2022)

Magnetic properties of Fe(3)O(4) antidot arrays synthesized by AFIR: atomic layer deposition, focused ion beam and thermal reduction
por: Palma, Juan L, et al.
Publicado: (2018)

Optimal Antithrombotic Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Focused Review on High Bleeding Risk
por: Matsuura, Yunosuke, et al.
Publicado: (2022)

Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study
por: Reuwer, Anne Q., et al.
Publicado: (2011)

Oxidative Stress in the Pathogenesis of Antiphospholipid Syndrome: Implications for the Atherothrombotic Process
por: Nocella, Cristina, et al.
Publicado: (2021)

Cardiovascular Events in Patients with Atherothrombotic Disease: A Population-Based Longitudinal Study in Taiwan
por: Lee, Wen-Hsien, et al.
Publicado: (2014)

New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease
por: Preston Mason, R.
Publicado: (2019)

Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations
por: Cho, Sung Won, et al.
Publicado: (2019)

Study design of GENERAL (general practitioners and embolism prevention in NVAF patients treated with rivaroxaban: Real-life evidence): A multicenter prospective cohort study in primary care physicians to investigate the effectiveness and safety of rivaroxaban in Japanese patients with NVAF
por: Kusano, Kengo, et al.
Publicado: (2017)

Changes in Antithrombotic Therapy Over Time and Durability of a Prasugrel WOEST-Like Regimen for Percutaneous Coronary Intervention Patients With Atrial Fibrillation　― Post Hoc Analysis of the PENDULUM Mono and PENDULUM Registries ―
por: Nakao, Koichi, et al.
Publicado: (2022)

MRAS Genetic Variation Is Associated with Atherothrombotic Stroke in the Han Chinese Population
por: Liu, Hua, et al.
Publicado: (2013)

Serum semaphorin 7A is associated with the risk of acute atherothrombotic stroke
por: You, Tao, et al.
Publicado: (2019)

Synthesis and Preliminary Evaluation of N-Oxide Derivatives for the Prevention of Atherothrombotic Events
por: Rosseto, Leandro Augusto, et al.
Publicado: (2015)

Atherothrombotic risk factors & premature coronary heart disease in India: A case-control study
por: Panwar, Raja Babu, et al.
Publicado: (2011)

One third of hospital costs for atherothrombotic disease are attributable to readmissions: a linked data analysis
por: Atkins, Emily R, et al.
Publicado: (2014)

The High-Risk Plaque Initiative: Primary Prevention of Atherothrombotic Events in the Asymptomatic Population
por: Falk, Erling, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ikpbs9dliusrsv926ksbj1oufa